What are Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (HUCT-MSCs)?
Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (HUCT-MSCs) are a promising source of stem cells for regenerative medicine due to their self-renewal capacity, multipotency, and low immunogenicity. These cells can differentiate into various cell types, including osteoblasts, chondrocytes, and adipocytes, and are capable of secreting cytokines that support tissue repair and modulate immune responses.
Key advantages of HUCT-MSCs include:
-
Noninvasive harvesting from umbilical cord tissue, which is typically discarded after birth.
-
High proliferation and differentiation potential that exceeds that of bone marrow- and adipose-derived MSCs.
-
Immunomodulatory and anti-inflammatory properties, allowing their use in allogeneic transplants without significant risk of rejection, as they do not express HLA-DR, the antigen responsible for immune rejection.
-
Abundant availability in Wharton’s jelly, the gelatinous substance within the umbilical cord.
Research supports their therapeutic potential in treating a wide range of conditions, including systemic lupus erythematosus, multiple sclerosis, type 1 and 2 diabetes, rheumatoid arthritis, spinal cord injury, heart failure, and graft-versus-host disease. A recent phase I/II clinical trial confirmed their safety and efficacy in treating aging frailty, marking a significant step toward clinical application.
Ongoing research emphasizes the need for standardized cell banking, quality control, and long-term safety evaluation, including monitoring for tumorigenicity, to fully realize their potential in advanced therapy medicinal products.
